Chemsynth Drugs & Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 2.00 Cr
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -9.54%
- Profit Growth -65.49%
- Ebitda 1260.48%
- Net Worth 171.16%
- Total Assets 22.65%
About Chemsynth Drugs & Pharmaceuticals
Chemsynth Drugs & Pharmaceuticals Private Limited (CDPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 01 March 2011 and has a history of 13 years and 11 months. Its registered office is in Delhi, India.
The Corporate was formerly known as Abil Chem Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kusum Sharma and Hari Sharma serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100DL2011PTC215053
-
Company No.
215053
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Mar 2011
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Chemsynth Drugs & Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kusum Sharma
|
Director | 09-Jun-2014 | Current |
|
Hari Sharma
|
Director | 01-Mar-2011 | Current |
Financial Performance of Chemsynth Drugs & Pharmaceuticals.
Chemsynth Drugs & Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.54% decrease. The company also saw a substantial fall in profitability, with a 65.49% decrease in profit. The company's net worth Soared by an impressive increase of 171.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chemsynth Drugs & Pharmaceuticals?
In 2023, Chemsynth Drugs & Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Alchemist Chemsynth Pharma Private LimitedKusum Sharma and Hari Sharma are mutual person
-
Vicint Biosciences Private Limited
Hari Sharma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Chemsynth Drugs & Pharmaceuticals?
Unlock and access historical data on people associated with Chemsynth Drugs & Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemsynth Drugs & Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemsynth Drugs & Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
